Metastatic Melanoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

(Albany, US) On October 07, 2026- DelveInsight’s, “Metastatic Melanoma Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Melanoma pipeline landscape. It covers the Metastatic Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Melanoma Pipeline @ https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight

Key Takeaways from the Metastatic Melanoma Pipeline Report

• On October 01, 2026- Iovance Biotherapeutics Inc. highlighted a Phase 2 study of the lifileucel treatment regimen in participants who previously received treatment for unresectable or metastatic (advanced) melanoma with 1 prior line of an anti-programmed cell death protein-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agent or whose melanoma progressed during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (early relapse). Participants who have BRAF V600 mutation positive melanoma may have received or refused 1 additional prior line treatment with a BRAF inhibitor.
• On September 29, 2026- University of Wisconsin, Madison conducted a phase 1b/2 study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.
• DelveInsight’s Metastatic Melanoma pipeline report depicts a robust space with 75+active players working to develop 75+ pipeline therapies for Metastatic Melanoma treatment.
• The leading Metastatic Melanoma Companies such as Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS and others.
• Promising Metastatic Melanoma Pipeline Therapies such as TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others

Stay ahead with the most recent pipeline outlook for Metastatic Melanoma @ Metastatic Melanoma Treatment Drugs

Metastatic Melanoma Overview

Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and sixth most common malignancy in females. Metastatic melanoma is a disease that occurs when the cancerous cells from the original tumor (primary tumor) get loose, spread by traveling through the lymph or blood circulation, and start a new tumor (metastatic tumor) somewhere else. Once it spreads, or metastasizes, the disease is known as metastatic melanoma. This type of melanoma may typically occur during stage 3 or stage 4. Common melanoma metastasis sites include the lymph nodes, lungs, liver, bones and brain.

Metastatic Melanoma Emerging Drugs Profile

• EVX 01: Evaxion Biotech

EVX-01, is a novel personalized cancer immunotherapy based on Evaxion’s proprietary PIONEER™ AI technology. EVX-01 is safe and has encouraging early indications of clinically and meaningful antitumor activity. Data showed EVX-01 is capable of eliciting T-cell responses in a clinical setting where the patients received concurrent standard immune therapy, i.e. anti-PD-1 treatment. Results demonstrated an antitumor effect in combination with anti-PD-1 treatment. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

• IN 10018: InxMed

IN10018 is a potent and highly selective adenosine triphosphate competitive FAK inhibitor, and InxMed has its exclusive global development and commercial operation rights. Early clinical data on IN10018 showed its safety and efficacy in multiple tumor types, and the latest research results and preclinical data demonstrated that IN10018 can also be effective in combination therapies. It is expected to overcome the tumor-associated fibrosis barrier and improve local immunity, and therefore has the potential to act as an important anchor molecule in synergy with different therapeutic modalities including immunotherapy, chemotherapy, and targeted therapy. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Melanoma.

• AV MEL 1: AiVita Biomedical

AV MEL 1, is an investigational drug being developed by AiVita Biomedical. AIVITA has received IND approval to begin a Phase 1B trial investigating its cancer vaccine in patients with metastatic melanoma plus checkpoint inhibitors.

The Metastatic Melanoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.
• Metastatic Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market

Explore groundbreaking therapies and clinical trials in the Metastatic Melanoma Pipeline @ New Metastatic Melanoma Drugs

Metastatic Melanoma Companies

Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS and others.

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Metastatic Melanoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Learn about new drugs, pipeline developments with DelveInsight’s expert analysis @ Metastatic Melanoma Market Drivers and Barriers

Scope of the Metastatic Melanoma Pipeline Report

• Coverage- Global
• Metastatic Melanoma Companies- Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS and others.
• Metastatic Melanoma Pipeline Therapies- TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, IO102-IO103, CMP-001, EVX-01, APX005M, BCD-217, Pixatimod, Selinexor, Relatlimab, V937, VB10.NEO, and others
• Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth Metastatic Melanoma Pipeline report today! @ Metastatic Melanoma Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Melanoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EVX 01: Evaxion Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IN 10018: InxMed
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Melanoma Key Companies
21. Metastatic Melanoma Key Products
22. Metastatic Melanoma Unmet Needs
23. Metastatic Melanoma Market Drivers and Barriers
24. Metastatic Melanoma Future Perspectives and Conclusion
25. Metastatic Melanoma Analyst Views
26. Metastatic Melanoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight